Menu Search
Equities

Knight Therapeutics Inc

GUD:TOR

Knight Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)5.27
  • Today's Change-0.03 / -0.57%
  • Shares traded78.75k
  • 1 Year change-0.57%
  • Beta0.5177
Data delayed at least 15 minutes, as of Nov 22 2024 20:46 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CADIncome statement in CADView more

Year on year Knight Therapeutics Inc grew revenues 11.80% from 293.56m to 328.20m while net income improved from a loss of 29.89m to a smaller loss of 16.84m.
Gross margin48.26%
Net profit margin-8.81%
Operating margin0.38%
Return on assets-3.11%
Return on equity-3.87%
Return on investment-3.53%
More ▼

Cash flow in CADView more

In 2023, cash reserves at Knight Therapeutics Inc fell by 12.92m. However, the company earned 35.94m from its operations for a Cash Flow Margin of 10.95%. In addition the company generated 29.34m cash from investing, though they paid out 81.00m more in financing than they received.
Cash flow per share0.1951
Price/Cash flow per share26.89
Book value per share7.66
Tangible book value per share4.05
More ▼

Balance sheet in CADView more

Knight Therapeutics Inc has a Debt to Total Capital ratio of 7.00%, a higher figure than the previous year's 6.69%.
Current ratio3.36
Quick ratio2.39
Total debt/total equity0.0752
Total debt/total capital0.07
More ▼

Growth rates in CAD

Year on year, growth in earnings per share excluding extraordinary items increased 39.79%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		-373.37
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.